Forendo Pharma Oy
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Forendo Pharma Oy
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.